{
  "variants": [
    {
      "variant": "DJ-1 L10P",
      "gene": "DJ-1",
      "protein_change": "L10P",
      "variant_string": "DJ-1 L10P",
      "functional_evidence_aim": "Pathogenic",
      "steps": {
        "step_1": {
          "question": "Define the disease mechanism.",
          "answer": "Yes. The abstract states that DJ-1 mutations cause autosomal recessive early-onset parkinsonism, and the assays focus on protein stability, dimerization, and solubility, which are relevant to pathogenic mechanisms."
        },
        "step_2": {
          "question": "Evaluate applicability of the assay.",
          "answer": "Yes. The assays (protein stability, dimerization, solubility) directly assess functional defects linked to DJ-1 dysfunction in Parkinson's disease."
        },
        "step_3": {
          "question": "Check basic controls and replicates (step 3a).",
          "answer": "Yes for controls (WT and L166P as normal/abnormal controls), but no explicit mention of replicates in the abstract."
        },
        "step_3b": {
          "question": "Accepted/validated assay (step 3b).",
          "answer": "Yes. Protein stability, dimerization, and solubility assays are standard techniques in the field."
        },
        "step_4": {
          "question": "Statistical analyses (step 4a).",
          "answer": "No. The abstract does not mention statistical tests, p-values, or OddsPath calculations."
        },
        "step_4b": {
          "question": "Number of benign/pathogenic controls (step 4b).",
          "answer": "2 (WT and L166P). <10 controls, so evidence strength is 'Max PS3_supporting'."
        }
      },
      "evidence_strength": "PS3_supporting"
    },
    {
      "variant": "DJ-1 L166P",
      "gene": "DJ-1",
      "protein_change": "L166P",
      "variant_string": "DJ-1 L166P",
      "functional_evidence_aim": "Pathogenic",
      "steps": {
        "step_1": {
          "question": "Define the disease mechanism.",
          "answer": "Yes. The abstract states that DJ-1 mutations cause autosomal recessive early-onset parkinsonism, and the assays focus on protein stability, dimerization, and solubility, which are relevant to pathogenic mechanisms."
        },
        "step_2": {
          "question": "Evaluate applicability of the assay.",
          "answer": "Yes. The assays (protein stability, dimerization, solubility) directly assess functional defects linked to DJ-1 dysfunction in Parkinson's disease."
        },
        "step_3": {
          "question": "Check basic controls and replicates (step 3a).",
          "answer": "Yes for controls (WT and L10P as normal/abnormal controls), but no explicit mention of replicates in the abstract."
        },
        "step_3b": {
          "question": "Accepted/validated assay (step 3b).",
          "answer": "Yes. Protein stability, dimerization, and solubility assays are standard techniques in the field."
        },
        "step_4": {
          "question": "Statistical analyses (step 4a).",
          "answer": "No. The abstract does not mention statistical tests, p-values, or OddsPath calculations."
        },
        "step_4b": {
          "question": "Number of benign/pathogenic controls (step 4b).",
          "answer": "2 (WT and L10P). <10 controls, so evidence strength is 'Max PS3_supporting'."
        }
      },
      "evidence_strength": "PS3_supporting"
    },
    {
      "variant": "DJ-1 P158DEL",
      "gene": "DJ-1",
      "protein_change": "P158DEL",
      "variant_string": "DJ-1 P158DEL",
      "functional_evidence_aim": "Pathogenic",
      "steps": {
        "step_1": {
          "question": "Define the disease mechanism.",
          "answer": "Yes. The abstract states that DJ-1 mutations cause autosomal recessive early-onset parkinsonism, and the assays focus on protein stability, dimerization, and solubility, which are relevant to pathogenic mechanisms."
        },
        "step_2": {
          "question": "Evaluate applicability of the assay.",
          "answer": "Yes. The assays (protein stability, dimerization, solubility) directly assess functional defects linked to DJ-1 dysfunction in Parkinson's disease."
        },
        "step_3": {
          "question": "Check basic controls and replicates (step 3a).",
          "answer": "Yes for controls (WT and L166P as normal/abnormal controls), but no explicit mention of replicates in the abstract."
        },
        "step_3b": {
          "question": "Accepted/validated assay (step 3b).",
          "answer": "Yes. Protein stability, dimerization, and solubility assays are standard techniques in the field."
        },
        "step_4": {
          "question": "Statistical analyses (step 4a).",
          "answer": "No. The abstract does not mention statistical tests, p-values, or OddsPath calculations."
        },
        "step_4b": {
          "question": "Number of benign/pathogenic controls (step 4b).",
          "answer": "2 (WT and L166P). <10 controls, so evidence strength is 'Max PS3_supporting'."
        }
      },
      "evidence_strength": "PS3_supporting"
    }
  ]
}